Last reviewed · How we verify

Rosuvastatin alone

Gachon University Gil Medical Center · FDA-approved active Small molecule Under review

Rosuvastatin alone is a HMG-CoA reductase inhibitor (statin) Small molecule drug developed by Gachon University Gil Medical Center. It is currently FDA-approved for Hypercholesterolemia and dyslipidemia, Primary prevention of cardiovascular disease, Secondary prevention of cardiovascular events in patients with established coronary artery disease. Also known as: Rosuvastatin alone therapy.

Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.

Rosuvastatin is a small molecule used in the treatment of various conditions, including hyperlipidemia. It has been studied in clinical trials for its effects on healthy participants, hypertension, and malaria, among other conditions.

At a glance

Generic nameRosuvastatin alone
Also known asRosuvastatin alone therapy
SponsorGachon University Gil Medical Center
Drug classHMG-CoA reductase inhibitor (statin)
TargetHMG-CoA reductase
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Rosuvastatin is a statin that competitively inhibits HMG-CoA reductase, which catalyzes the conversion of HMG-CoA to mevalonate in the cholesterol biosynthetic pathway. This inhibition decreases hepatic cholesterol production, leading to upregulation of LDL receptors on hepatocytes and increased clearance of LDL cholesterol from the bloodstream. The net result is a significant reduction in serum LDL cholesterol and triglycerides, with modest increases in HDL cholesterol.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Rosuvastatin alone

What is Rosuvastatin alone?

Rosuvastatin alone is a HMG-CoA reductase inhibitor (statin) drug developed by Gachon University Gil Medical Center, indicated for Hypercholesterolemia and dyslipidemia, Primary prevention of cardiovascular disease, Secondary prevention of cardiovascular events in patients with established coronary artery disease.

How does Rosuvastatin alone work?

Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.

What is Rosuvastatin alone used for?

Rosuvastatin alone is indicated for Hypercholesterolemia and dyslipidemia, Primary prevention of cardiovascular disease, Secondary prevention of cardiovascular events in patients with established coronary artery disease.

Who makes Rosuvastatin alone?

Rosuvastatin alone is developed and marketed by Gachon University Gil Medical Center (see full Gachon University Gil Medical Center pipeline at /company/gachon-university-gil-medical-center).

Is Rosuvastatin alone also known as anything else?

Rosuvastatin alone is also known as Rosuvastatin alone therapy.

What drug class is Rosuvastatin alone in?

Rosuvastatin alone belongs to the HMG-CoA reductase inhibitor (statin) class. See all HMG-CoA reductase inhibitor (statin) drugs at /class/hmg-coa-reductase-inhibitor-statin.

What development phase is Rosuvastatin alone in?

Rosuvastatin alone is FDA-approved (marketed).

What are the side effects of Rosuvastatin alone?

Common side effects of Rosuvastatin alone include Muscle pain or myalgia, Elevated liver enzymes (ALT/AST), Headache, Nausea, Rhabdomyolysis (rare).

What does Rosuvastatin alone target?

Rosuvastatin alone targets HMG-CoA reductase and is a HMG-CoA reductase inhibitor (statin).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing